Tag
A 40-year retrospective study of 569 patients with ocular metastases reveals persistently poor survival, dominated by breast and lung primaries, with vision often preserved through treatment despite no significant survival improvements over
Omission of sentinel lymph node biopsy (SLNB) in select postmenopausal patients with early HR+/HER2- breast cancer and negative axillary ultrasound is feasible and safe, reducing surgical morbidity without compromising short-term outcomes.
CDK4/6 inhibitor therapy in hormone receptor-positive breast cancer is linked to increased corneal epithelial alterations, including punctate epitheliopathy and vortex keratopathy, independent of aromatase inhibitor effects or tear film dys
This large-scale study reveals that adolescent and young adult women with breast cancer predominantly undergo mastectomy and experience comparable perioperative outcomes to older women, despite a higher metastatic burden.
In the four-arm SleepCARE trial of 219 women receiving breast cancer chemotherapy, brief CBT-I significantly improved insomnia while bright light therapy did not beat sleep hygiene education. Neither helped fatigue, and combining the two added burden without benefit.
In women aged 65 and older with cT2N0 hormone receptor-positive, HER2-negative breast cancer, sentinel lymph node biopsy rarely alters adjuvant therapy plans, supporting a more individualized approach to axillary staging in this population.
Breast cancer independently increases atrial fibrillation risk via tumour-secreted ADAM10, which induces atrial fibrosis through the Ephrin B2 signaling pathway, offering a potential new therapeutic target.
This study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.
The BrIMA trial demonstrates that specimen PET-CT imaging significantly improves intraoperative detection of positive margins during breast-conserving surgery for early-stage breast cancer, reducing re-excision rates and enhancing surgical
Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-ter
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.
This WISDOM Study analysis found that most women with breast cancer pathogenic variants would not have been flagged for high-risk screening by clinical or polygenic risk models alone, supporting population-based genetic testing.
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.
This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.
A national database study found that neoadjuvant chemotherapy was linked to worse overall survival than upfront surgery in node-positive hormone receptor-positive, HER2-negative breast cancer, except in patients who achieved nodal complete
A major study reveals that safety-net hospitals—serving vulnerable Medicaid and uninsured patients—deliver breast cancer care and survival outcomes on par with other hospitals, challenging assumptions about quality disparities in resource-c
A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.
The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and h
